Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
PatSnap Eureka Desktop
NEWAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Law Firms
Life Sciences
High-Tech
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Dato-DXd vs. SG in TNBC: compare TROP2 ADC mechanisms, linker-payload design, clinical signals, and IP landscape for datopotamab deruxtecan and sacituzumab govitecan.
Article | Report How does laser-based metal deposition compare to traditional welding for turbine blade tip restoration in MRO? Explore the key process differences, trade-offs, and patent trends.
Article | Report NLRP3 inhibitor VTX3232 is advancing toward Phase III in Parkinson's disease and cardiometabolic conditions — and Sanofi holds a right of first negotiation. Here's what the patent data reveals.
Article | Report How engineers use multi-physics co-simulation to design next-generation power electronic converters — thermal, EM, mechanical and circuit domain coupling explained.
Article | Report Fenebrutinib's Phase III trials in progressive MS target smoldering lesions via CNS-penetrant BTK inhibition. How does Roche's bet compare to tolebrutinib?
Article | Report How AI-powered generative design transforms the engineering workflow for lightweight satellite structural components — topology optimization, multi-objective automation, and manufacturing integration.
Article | Report TERN-701, Terns Pharmaceuticals' STAMP inhibitor targeting BCR-ABL's myristoyl pocket, prompted Merck's $6.7B acquisition. Explore the CML pipeline race.
Article | Report How engineers validate electromagnetic compatibility of active implantable devices under ISO 14117 — testing frameworks, immunity protocols, and regulatory requirements explained.
Article | Report Scholar Rock's apitegromab targets latent myostatin in SMA patients on risdiplam or nusinersen. Explore the patent landscape and muscle-targeted therapy rationale.
Article | Report How does robot-assisted minimally invasive surgery differ from conventional laparoscopy? Explore the key engineering design constraints shaping next-gen surgical systems.
Article | Report How engineers design explosion-proof enclosures for electronic systems in hazardous environments: ATEX, IECEx, flameproof methods, and certification strategies.
Article | Report Iberdomide's EXCALIBER-RRMM Phase III trial positions CELMoD agents as the next-generation successor to lenalidomide in relapsed/refractory multiple myeloma.
Article | Report How AI-assisted code generation is reshaping firmware development workflows for embedded systems engineers — productivity, IP, and best practices.
Article | Report MET/VEGFR inhibitor zanzalintinib combined with atezolizumab targets metastatic colorectal cancer via dual pathway blockade. Explore the molecular rationale and IP landscape.
Article | Report Lanifibranor's NATiV3 Phase III readout is the most anticipated MASH event of 2026. Explore the pan-PPAR mechanism, histological endpoints, and competitive pipeline.